Clinical Trial Update: A Study to Assess Safety and Efficacy of ASP015K in Participants With Rheumatoid Arthritis (RA) Who Had an Inadequate Response or Intolerance to Methotrexate (MTX) [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating ASP015K for rheumatoid arthritis in MTX-inadequate responders has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• ASP015K

Snippet

Sponsor: Astellas Pharma China, Inc. | Conditions: Rheumatoid Arthritis (RA) | Phase 3 | Status: COMPLETED